Education
About Us
Working with TipRanks
Follow Us
AnaptysBio (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
$50.10
-$0.23(-1.55%)
At close: 4:00 PM EST
$50.10
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$12.21 - $51.43
Previous CloseN/A
Volume154.73K
Average Volume (3M)481.17K
Market Cap
$1.39B
Enterprise Value$986.03M
Total Cash (Recent Filing)$248.96M
Total Debt (Recent Filing)$346.45M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 09, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding27,688,470
10 Day Avg. Volume378,401
30 Day Avg. Volume481,170
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)5.30
Price to Sales (P/S)4.12
P/FCF Ratio-2.77
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue5.82
Enterprise Value/Gross Profit59.88
Enterprise Value/Ebitda-215.76
Forecast
1Y Price Target
$71.50Price Target Upside42.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.44
Revenue Forecast (FY)$204.72M
Bulls Say, Bears Say
Bulls Say
Promising Drug PipelineAnaptysBio's development pipeline includes promising assets like rosnilimab and ANB033, with all data timelines on track, showing potential for future advancements.
Royalty Stream PotentialRoyalty Management Co will focus on Jemperli royalties from GSK, with potential peak sales translating to significant royalties for ANAB.
Strategic Business SeparationAnaptysBio announced plans to separate its Biopharma operations and established royalty revenue business into two separately traded public companies, aiming to maximize value.
Bears Say
Litigation RiskIf Anaptys loses or settles unfavorably, the company may face diminished revenue from Jemperli or further legal costs, which could impact the stock price negatively.
Potential Royalty ReductionA worst case scenario would be if GSK wins and receives an irrevocable license to Jemperli and is able to reduce its royalty rates and milestone payments by 50%.
Trial Endpoint FailurePhase 2 rosnilimab trial in UC does not meet primary endpoint; T cells likely not a driver of UC pathogenesis.
AnaptysBio News
ANAB FAQ
What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest stock price was $12.21 and its highest was $51.43 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.39B.
When is AnaptysBio’s upcoming earnings report date?
AnaptysBio’s upcoming earnings report date is Mar 09, 2026 which is in 70 days.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on Nov 04, 2025. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of -$1.214 by $1.734.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate is 0.88.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 27,688,470 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of $0.52 in its last earnings report, beating expectations of -$1.214. Following the earnings report the stock price went up 3.627%.
Which hedge fund is a major shareholder of AnaptysBio?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.50 (42.71% Upside)
$71.50 (42.71% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $193.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
264.62%
12-Months-Change
Fundamentals
Return on Equity
-308.02%
Trailing 12-Months
Asset Growth
-28.44%
Trailing 12-Months
Company Description
AnaptysBio
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$71.50
▲(42.71% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
Currently, No data available
---